Be in the know about the most anticipated aesthetic procedure.
How Personal Information Provided By You May Be Used.
Disclosures to Third Parties Assisting In Our Operations. Cytrellis may share your PI under confidentiality agreements with other companies that work with, or on behalf of, Cytrellis, to provide products and services. These companies may use your PI to assist Cytrellis in its operations. These companies do not, however, have any independent right to share this information. Disclosures Under Special Circumstances. We may disclose your PI to respond to subpoenas, court orders, legal process or governmental regulations, or to establish or exercise our legal rights or defend against legal claims. We may also disclose your PI if we believe it is necessary to share information in order to investigate, prevent or take action regarding illegal activities, suspected fraud, situations involving potential threats to the physical safety of any person, or as otherwise required by law.
Each time a visitor comes to the Website, Cytrellis collects some information to improve the overall quality of the visitor’s online experience.
Aggregated Data. Cytrellis collects aggregate queries for internal reporting and also counts, tracks, and aggregates the visitor’s activity into Cytrellis’s analysis of general traffic-flow at the Website. Cytrellis may also remove personal identifiers from PI and maintain it in aggregate form that may later be combined with other information to generate anonymous, aggregated statistical information. Cytrellis may share, publicly or privately, anonymized or aggregated information from the Website. If Cytrellis shares aggregate information, it will do so in a manner that no individual can be identified.
Web Server Logs and IP Addresses. An Internet Protocol (“IP”) address is a number that automatically identifies the computer/device you have used to access the Internet. The IP address enables our server to send you the web pages that you want to visit, and it may disclose the server owned by your Internet Service Provider. Cytrellis may use IP addresses to conduct website analyses and performance reviews and to administer the Website.
Cookies and Web Beacons. Cookies are pieces of information that a website transfers to a user’s computer for purposes of storing information about a user’s preferences.
Cytrellis takes measures it believes are reasonably designed to protect the PI it receives from you from unauthorized access, use and alteration. We believe, however, that a persistent attacker with sufficient resources would be able to defeat our security measures. Therefore, we provide no guarantee that your PI will remain secure.
Some Internet browsers include the ability to transmit “Do Not Track” signals. Since uniform standards for “Do Not Track” signals have not yet been adopted, Cytrellis does not process or respond to “Do Not Track” signals.
Under Age 13
Cytrellis understands the importance of protecting children’s privacy in the interactive online world. The Website is not designed for, or intentionally targeted at, children 13 years of age or younger. It is not our policy to intentionally collect or maintain information about anyone under the age of 13. No one under the age of 13 should submit any PI to Cytrellis and/or the Website, and if we learn that we have collected or received PI from a child under 13, we will delete that information. If your child has sent us personal information and you would like it removed, please send an e-mail to email@example.com requesting removal.
Under Age 18
Minors under 18 years of age may have the PI that they have provided to Cytrellis through this Website deleted by sending an e-mail to firstname.lastname@example.org requesting deletion. Please note that, while we make reasonable efforts to comply with such requests, deletion of your PI does not ensure complete and comprehensive removal of that data from all systems.
California Civil Code Section § 1798.83 permits users of our Website that are California residents to request certain information regarding our disclosure of PI to third parties for their direct marketing purposes. To make such a request, you may contact us by e-mail at email@example.com.
You may review and request changes to your PI that Cytrellis has collected, including the removal of your PI from Cytrellis’s databases in order to prevent receipt of future communications, using any of the following options:
You can send your request via e-mail to: firstname.lastname@example.org
You can mail your request to the following postal address:
Cytrellis Biosystems, Inc.
299C Washington Street
Woburn, MA 02210
The ellacor® System with Micro-Coring® technology is indicated for use by medical professionals for the treatment of moderate and severe wrinkles in the mid and lower face in adults aged 22 years or older with Fitzpatrick skin types I-IV.
Your medical professional will discuss the following side effects with you prior to treatment. Proper pre- and post-treatment care reduces the risk of these side effects; however, some conditions may or may not resolve over time. Side effects associated with this procedure may include: redness, swelling, bruising, burning, dryness, roughness, tightness/pulling of skin, crusting, pain/discomfort, tenderness, tingling, bleeding, numbness, skin peeling, or circular marks on skin.
Other side effects not commonly observed with this procedure may include: itching, hyper/hypo pigmentation, hematoma, infection, scarring, skin irregularities, skin necrosis, uneven appearance of the treated regions (left and right sides of face), or anesthesia toxicity (anesthesia-related complications may include allergic reaction and possibly death).
The ellacor® procedure should not be used for the treatment of areas of skin with dermatosis (e.g. skin tumors, keloids or in case of predisposition to keloids, solar keratosis, warts, or birthmarks), area within the bony orbital rim; mucous membranes; areas where silicone or synthetic material is implanted.
The ellacor® procedure should not be used on patients that are pregnant or nursing mothers, suffering from open wounds, sores, or irritated skin in the treatment area, have an allergy to stainless steel or allergy to topical, oral, or injected medications or preparations that may be used during the procedure, such as petrolatum, lidocaine, bupivacaine, chlorhexidine, or povidone-iodine. Patients that have a history or presence of any clinically significant bleeding disorder, have dermatological or autoimmune conditions that may affect the treatment outcome; these may include, but are not limited to: actinic keratosis, raised nevi, rosacea, melasma, active acne, cutaneous papules/nodules, active inflammatory lesions, dermatitis, psoriasis, cellulitis, urticarial folliculitis, acute inflammatory phase of scleroderma, rheumatoid arthritis, eczema, psoriasis, allergic dermatitis, collagen disorders, or lupus should not be treated with the ellacor® procedure. Additionally, patients that have systemic infections or acute local skin infections such as Hepatitis disorders type A, B, C, D, E or F or HIV infection, take a high dose of anti-coagulants or blood-thinning substances (e.g. aspirin, nonsteroidal anti-inflammatory drugs, NSAIDs, warfarin, heparin, acetylsalicylic acid during the previous fourteen (14) days), are on courses of chemotherapy, high-dose corticosteroid use, or radiation in the treatment area, have undergone plastic surgery of the face within the last twelve (12) months or have any facial surgical scars less than twelve (12) months old, have undergone injections of dermal fillers, fat, or botulinum toxin, as well as any minimally invasive/invasive skin treatment in the treatment area during the previous six (6) months, or have scars less than six (6) months old in the treatment area should not be treated with the ellacor® procedure.
Appropriateness for treatment is based on the clinical assessment of the patient by the treating physician. Use caution when treating patients with the following conditions or taking the following medications: